133 related articles for article (PubMed ID: 26320477)
1. Incidence, Risk Factors, and Outcomes of Febrile Neutropenia in Thai Hematologic Malignancy Patients Receiving Chemotherapy: A 6-year Retrospective Cohort Study.
Limvorapitak W; Khawcharoenporn T
Asian Pac J Cancer Prev; 2015; 16(14):5945-50. PubMed ID: 26320477
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
[TBL] [Abstract][Full Text] [Related]
3. Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494).
Morrison VA; Weller EA; Habermann TM; Li S; Fisher RI; Cheson BD; Peterson BA
Leuk Lymphoma; 2017 Aug; 58(8):1814-1822. PubMed ID: 27967294
[TBL] [Abstract][Full Text] [Related]
4. Importance of Risk Factors for Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified as High-Risk in Guidelines for Myeloid Growth Factor Use.
Weycker D; Li X; Barron R; Wu H; Morrow PK; Xu H; Reiner M; Garcia J; Mhatre SK; Lyman GH
J Natl Compr Canc Netw; 2015 Aug; 13(8):979-86. PubMed ID: 26285243
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
[TBL] [Abstract][Full Text] [Related]
6. Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan.
Yokoyama M; Kusano Y; Takahashi A; Inoue N; Ueda K; Nishimura N; Mishima Y; Terui Y; Nukada T; Nomura T; Hatake K
Support Care Cancer; 2017 Nov; 25(11):3313-3320. PubMed ID: 28551843
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk factors for febrile neutropenia of patients with diffuse large B-cell lymphoma receiving R-CHOP-21 in China.
Zheng W; Chen Z; Zhu S; Cheng L; Hu Y; Yang Y; Tan M; Ning H; Guan L
Support Care Cancer; 2023 Dec; 32(1):43. PubMed ID: 38200251
[TBL] [Abstract][Full Text] [Related]
8. Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
Kawahira M; Yokota T; Hamauchi S; Kawai S; Yoshida Y; Onozawa Y; Tsushima T; Todaka A; Machida N; Yamazaki K; Fukutomi A; Yasui H
Int J Clin Oncol; 2018 Dec; 23(6):1189-1195. PubMed ID: 29948238
[TBL] [Abstract][Full Text] [Related]
9. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.
Mäenpää J; Varthalitis I; Erdkamp F; Trojan A; Krzemieniecki K; Lindman H; Bendall K; Vogl FD; Verma S
Breast; 2016 Feb; 25():27-33. PubMed ID: 26801413
[TBL] [Abstract][Full Text] [Related]
10. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
Aarts MJ; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Borm GF; Tjan-Heijnen VC
J Clin Oncol; 2013 Dec; 31(34):4290-6. PubMed ID: 23630211
[TBL] [Abstract][Full Text] [Related]
11. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
12. The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum.
Fujiwara T; Kenmotsu H; Naito T; Kawamura T; Mamesaya N; Kotake M; Kobayashi H; Omori S; Nakashima K; Wakuda K; Ono A; Taira T; Murakami H; Omae K; Mori K; Endo M; Takahashi T
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1229-1237. PubMed ID: 28455585
[TBL] [Abstract][Full Text] [Related]
13. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.
Hill G; Barron R; Fust K; Skornicki ME; Taylor DC; Weinstein MC; Lyman GH
J Med Econ; 2014 Jan; 17(1):32-42. PubMed ID: 24028444
[TBL] [Abstract][Full Text] [Related]
14. Mortality and admission to intensive care units after febrile neutropenia in patients with cancer.
Aagaard T; Reekie J; Jørgensen M; Roen A; Daugaard G; Specht L; Sengeløv H; Mocroft A; Lundgren J; Helleberg M
Cancer Med; 2020 May; 9(9):3033-3042. PubMed ID: 32144897
[TBL] [Abstract][Full Text] [Related]
15. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).
Pinter T; Klippel Z; Cesas A; Croitoru A; Decaestecker J; Gibbs P; Hotko Y; Jassem J; Kurteva G; Novotny J; O'Reilly S; Salek T; Reiner M; Morrow PK; Choi MR; Whittaker S; Blanke C
Clin Colorectal Cancer; 2017 Jun; 16(2):103-114.e3. PubMed ID: 28038865
[TBL] [Abstract][Full Text] [Related]
16. Risk Factors for Febrile Neutropenia in Children With Solid Tumors Treated With Cisplatin-based Chemotherapy.
Castelán-Martínez OD; Rodríguez-Islas F; Vargas-Neri JL; Palomo-Colli MA; López-Aguilar E; Clark P; Castañeda-Hernández G; Rivas-Ruiz R
J Pediatr Hematol Oncol; 2016 Apr; 38(3):191-6. PubMed ID: 26907640
[TBL] [Abstract][Full Text] [Related]
17. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Jin UR; Park JS
J Korean Med Sci; 2014 Nov; 29(11):1493-500. PubMed ID: 25408580
[TBL] [Abstract][Full Text] [Related]
18. The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis.
Do T; Medhekar R; Bhat R; Chen H; Niravath P; Trivedi MV
Breast Cancer Res Treat; 2015 Oct; 153(3):591-7. PubMed ID: 26337685
[TBL] [Abstract][Full Text] [Related]
19. Neutropenia during frontline treatment of advanced Hodgkin lymphoma: Incidence, risk factors, and management.
Sureda A; Domingo-Domenech E; Gautam A
Crit Rev Oncol Hematol; 2019 Jun; 138():1-5. PubMed ID: 31092364
[TBL] [Abstract][Full Text] [Related]
20. [Appropriate use of granulocyte-colony stimulating factor in treating hematologic malignancies].
Usui N
Rinsho Ketsueki; 2015 Oct; 56(10):2267-76. PubMed ID: 26458468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
